Skye Bioscience (SKYE) Treasury Shares (2015 - 2026)
Skye Bioscience (SKYE) posted quarterly Treasury Shares of $491551.0 for Q1 2026, down 2.3% year-over-year from $503113.0 in Q1 2025, and little changed quarter-over-quarter from $492488.0 in Q4 2025.
Skye Bioscience (SKYE) Treasury Shares (2015 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Treasury Shares for 11 consecutive years, with $491551.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Treasury Shares fell 2.3% year-over-year to $491551.0; the TTM figure through Mar 2026 stood at $491551.0 (down 2.3% YoY), while the FY2025 annual figure was $492488.0, down 2.11% from the prior year.
- Treasury Shares was little changed at $491551.0 in Q1 2026 per SKYE's latest filing, from $492488.0 in the prior quarter.
- Across five years, Treasury Shares topped out at $1.1 million in Q3 2024 and bottomed at $10665.0 in Q4 2022.
- Historically, Treasury Shares has averaged $657257.0 across 5 years, with a median of $503113.0 in 2024.
- Annual changes were most pronounced in 2022 — Treasury Shares sank 92.89% — and 2023, when it jumped 7849.15%.
- Skye Bioscience's Treasury Shares stood at $10665.0 in 2022, then surged by 7849.15% to $847777.0 in 2023, then sank by 40.66% to $503113.0 in 2024, then declined by 2.11% to $492488.0 in 2025, then declined by 0.19% to $491551.0 in 2026.
- Business Quant data shows SKYE's Treasury Shares at $491551.0 in Q1 2026, $492488.0 in Q4 2025, and $498426.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.96 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.72 Mn |
| 10 | Skye Bioscience | 10.86 Mn | 10.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 491,551.00 |
| Mar 31, 2026 | 491,551.00 |
| Dec 31, 2025 | 492,488.00 |
| Dec 31, 2025 | 492,488.00 |
| Sep 30, 2025 | 498,426.00 |
| Sep 30, 2025 | 498,426.00 |
| Jun 30, 2025 | 499,363.00 |
| Jun 30, 2025 | 499,363.00 |
| Mar 31, 2025 | 503,113.00 |
| Mar 31, 2025 | 503,113.00 |
| Dec 31, 2024 | 503,113.00 |
| Dec 31, 2024 | 503,113.00 |
| Sep 30, 2024 | 1.14 Mn |
| Sep 30, 2024 | 1.14 Mn |
| Jun 30, 2024 | 1.12 Mn |
| Jun 30, 2024 | 1.12 Mn |
| Mar 31, 2024 | 1.12 Mn |
| Mar 31, 2024 | 1.12 Mn |
| Dec 31, 2023 | 847,777.00 |
| Dec 31, 2023 | 847,777.00 |